2023-503573-38-00
Recruiting
Phase 1
Safety of stem cells in treatmemt of retinal diseases.
Bioinova a.s.1 site in 1 country10 target enrollmentStarted: March 1, 2026Last updated:
ConditionsRetinal degenerative diseases
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Bioinova a.s.
- Enrollment
- 10
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Hana Potočková
Scientific
Bioinova a.s.
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMDNCT07418177The First Affiliated Hospital with Nanjing Medical University9
Unknown
Not Applicable
新型干细胞治疗难治性眼病的临床应用前研究ChiCTR-ONN-16009353上海申康医院发展中心180
Recruiting
Not Applicable
A study to check how well the Bio-M Pathfinder rapid test identifies eye diseases in patientsCTRI/2025/11/097850NovoMol-Dx Private Limited200
Unknown
Not Applicable
人源 MSC-RPE 细胞移植治疗糖尿病视网膜病变的 有效性和安全性研究ChiCTR1800016870深圳市瑞普逊干细胞再生医学研究院30
Completed
Phase 1
Stem Cell Therapy for Outer Retinal DegenerationsAge Related Macular DegenerationStargardt's DiseaseExudative Age-related Macular DegenerationNCT02903576Federal University of São Paulo15